Cargando…
Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation
BACKGROUND: This study was performed to evaluate the clinical outcomes of hybrid treatment involving surgical resection and percutaneous radiofrequency ablation for patients with multiple lung metastases. METHODS: Seventeen patients (6 men, 11 women; median age, 52 years; range, 16–78 years) underwe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287015/ https://www.ncbi.nlm.nih.gov/pubmed/34106518 http://dx.doi.org/10.1111/1759-7714.14041 |
_version_ | 1783723830893608960 |
---|---|
author | Hasegawa, Takaaki Kuroda, Hiroaki Sakakura, Noriaki Sato, Yozo Chatani, Shohei Murata, Shinichi Yamaura, Hidekazu Nakada, Takeo Oya, Yuko Inaba, Yoshitaka |
author_facet | Hasegawa, Takaaki Kuroda, Hiroaki Sakakura, Noriaki Sato, Yozo Chatani, Shohei Murata, Shinichi Yamaura, Hidekazu Nakada, Takeo Oya, Yuko Inaba, Yoshitaka |
author_sort | Hasegawa, Takaaki |
collection | PubMed |
description | BACKGROUND: This study was performed to evaluate the clinical outcomes of hybrid treatment involving surgical resection and percutaneous radiofrequency ablation for patients with multiple lung metastases. METHODS: Seventeen patients (6 men, 11 women; median age, 52 years; range, 16–78 years) underwent hybrid treatment involving surgery and radiofrequency ablation to treat multiple lung metastases (median number, 4; range, 2–26) between May 2014 and February 2020. The primary lesions were colorectal carcinoma (n = 9), uterine endometrial carcinoma (n = 3), osteosarcoma (n = 2), renal cell carcinoma (n = 1), glottic carcinoma (n = 1), and fibrolamellar hepatocellular carcinoma (n = 1). Twenty‐four sessions each of surgery and radiofrequency ablation were performed. Safety, disease‐free survival, and overall survival were evaluated. Safety was assessed according to the Clavien‐Dindo Classification. RESULTS: A grade IVa adverse event of empyema developed in one patient (4%, 1/24) after surgery. A grade IIIa adverse event of pneumothorax and a grade II adverse event of lung abscess occurred in four (17%, 4/24) and one session (4%, 1/24) after radiofrequency ablation, respectively. During the median follow up of 34 months (range, 8–67 months), 10 patients (59%, 10/17) developed new metastases. The 5‐year disease‐free survival rate was 32%. Four or fewer lung metastases (p = 0.008) and metastases from colorectal carcinoma (p = 0.02) were factors significantly associated with longer disease‐free survival. One patient (6%, 1/17) died of tumor progression 29 months after initial treatment. The 5‐year overall survival rate was 88%. CONCLUSIONS: The strategy of hybrid treatment involving surgery and radiofrequency ablation may offer good outcomes for patients with multiple lung metastases. |
format | Online Article Text |
id | pubmed-8287015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-82870152021-07-21 Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation Hasegawa, Takaaki Kuroda, Hiroaki Sakakura, Noriaki Sato, Yozo Chatani, Shohei Murata, Shinichi Yamaura, Hidekazu Nakada, Takeo Oya, Yuko Inaba, Yoshitaka Thorac Cancer Original Articles BACKGROUND: This study was performed to evaluate the clinical outcomes of hybrid treatment involving surgical resection and percutaneous radiofrequency ablation for patients with multiple lung metastases. METHODS: Seventeen patients (6 men, 11 women; median age, 52 years; range, 16–78 years) underwent hybrid treatment involving surgery and radiofrequency ablation to treat multiple lung metastases (median number, 4; range, 2–26) between May 2014 and February 2020. The primary lesions were colorectal carcinoma (n = 9), uterine endometrial carcinoma (n = 3), osteosarcoma (n = 2), renal cell carcinoma (n = 1), glottic carcinoma (n = 1), and fibrolamellar hepatocellular carcinoma (n = 1). Twenty‐four sessions each of surgery and radiofrequency ablation were performed. Safety, disease‐free survival, and overall survival were evaluated. Safety was assessed according to the Clavien‐Dindo Classification. RESULTS: A grade IVa adverse event of empyema developed in one patient (4%, 1/24) after surgery. A grade IIIa adverse event of pneumothorax and a grade II adverse event of lung abscess occurred in four (17%, 4/24) and one session (4%, 1/24) after radiofrequency ablation, respectively. During the median follow up of 34 months (range, 8–67 months), 10 patients (59%, 10/17) developed new metastases. The 5‐year disease‐free survival rate was 32%. Four or fewer lung metastases (p = 0.008) and metastases from colorectal carcinoma (p = 0.02) were factors significantly associated with longer disease‐free survival. One patient (6%, 1/17) died of tumor progression 29 months after initial treatment. The 5‐year overall survival rate was 88%. CONCLUSIONS: The strategy of hybrid treatment involving surgery and radiofrequency ablation may offer good outcomes for patients with multiple lung metastases. John Wiley & Sons Australia, Ltd 2021-06-09 2021-07 /pmc/articles/PMC8287015/ /pubmed/34106518 http://dx.doi.org/10.1111/1759-7714.14041 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Hasegawa, Takaaki Kuroda, Hiroaki Sakakura, Noriaki Sato, Yozo Chatani, Shohei Murata, Shinichi Yamaura, Hidekazu Nakada, Takeo Oya, Yuko Inaba, Yoshitaka Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation |
title | Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation |
title_full | Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation |
title_fullStr | Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation |
title_full_unstemmed | Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation |
title_short | Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation |
title_sort | novel strategy to treat lung metastases: hybrid therapy involving surgery and radiofrequency ablation |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287015/ https://www.ncbi.nlm.nih.gov/pubmed/34106518 http://dx.doi.org/10.1111/1759-7714.14041 |
work_keys_str_mv | AT hasegawatakaaki novelstrategytotreatlungmetastaseshybridtherapyinvolvingsurgeryandradiofrequencyablation AT kurodahiroaki novelstrategytotreatlungmetastaseshybridtherapyinvolvingsurgeryandradiofrequencyablation AT sakakuranoriaki novelstrategytotreatlungmetastaseshybridtherapyinvolvingsurgeryandradiofrequencyablation AT satoyozo novelstrategytotreatlungmetastaseshybridtherapyinvolvingsurgeryandradiofrequencyablation AT chatanishohei novelstrategytotreatlungmetastaseshybridtherapyinvolvingsurgeryandradiofrequencyablation AT muratashinichi novelstrategytotreatlungmetastaseshybridtherapyinvolvingsurgeryandradiofrequencyablation AT yamaurahidekazu novelstrategytotreatlungmetastaseshybridtherapyinvolvingsurgeryandradiofrequencyablation AT nakadatakeo novelstrategytotreatlungmetastaseshybridtherapyinvolvingsurgeryandradiofrequencyablation AT oyayuko novelstrategytotreatlungmetastaseshybridtherapyinvolvingsurgeryandradiofrequencyablation AT inabayoshitaka novelstrategytotreatlungmetastaseshybridtherapyinvolvingsurgeryandradiofrequencyablation |